ALNYLAM PHARMACEUTICALS, INC. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2147f1c7-9b39-4c0a-adf5-27303ed6404f/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $3.7B | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-007497 |
| FY 2024 | $2.2B | 2024-01-01 – 2024-12-31 | evidence 0001178670-25-000026 |
| FY 2023 | $1.8B | 2023-01-01 – 2023-12-31 | evidence 0001178670-24-000008 |
| FY 2022 | $1.0B | 2022-01-01 – 2022-12-31 | evidence 0001178670-24-000008 |
| FY 2021 | $844.3M | 2021-01-01 – 2021-12-31 | evidence 0001178670-24-000008 |
| FY 2020 | $492.9M | 2020-01-01 – 2020-12-31 | evidence 0001178670-22-000013 |
| FY 2019 | $219.8M | 2019-01-01 – 2019-12-31 | evidence 0001178670-22-000013 |
| FY 2018 | $74.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003022 |
| FY 2017 | $89.9M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-003022 |
| FY 2016 | $47.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-003022 |
| FY 2010 | $100.0M | 2010-01-01 – 2010-12-31 | evidence 0000950123-11-015737 |
| FY 2009 | $100.5M | 2009-01-01 – 2009-12-31 | evidence 0000950123-11-015737 |
| FY 2008 | $96.2M | 2008-01-01 – 2008-12-31 | evidence 0000950123-11-015737 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ALNYLAM PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income